Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 7/20 | 0.39 |
| ▸ | DRD3 | P35462 | 5/20 | 0.39 |
| ▸ | DRD1 | P21728 | 3/20 | 0.39 |
| ▸ | DRD4 | P21917 | 3/20 | 0.39 |
| ▸ | DRD5 | P21918 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1201009 | 0.84 | ALDH1A1 (0.62) | ALDH1A1DRD2DRD3DRD1DRD4 | |
| SCHEMBL27672302 | 0.81 | ALDH1A1 (0.42) | ALDH1A1DRD2DRD3DRD1DRD4 | |
| SCHEMBL1712875 | 0.81 | DRD2 (0.43) | ALDH1A1DRD2DRD3DRD1DRD4 | |
| SCHEMBL6023587 | 0.78 | HTT (0.56) | LMNAMAPK1GAA | |
| SCHEMBL20124005 | 0.77 | CA2 (0.45) | ALDH1A1KMT2AMEN1LMNAMAPK1 | |
| SCHEMBL7787737 | 0.77 | SMN1; SMN2 (0.44) | ALDH1A1KMT2AMEN1LMNAMAPK1 | |
| SCHEMBL731975 | 0.77 | ALDH1A1 (0.43) | ALDH1A1KMT2AMEN1LMNAMAPK1 | |
| SCHEMBL29743115 | 0.77 | ALDH1A1 (0.43) | ALDH1A1KMT2AMEN1LMNAMAPK1 | |
| SCHEMBL8813181 | 0.76 | ALDH1A1 (0.44) | ALDH1A1KMT2AMEN1LMNAMAPK1 | |
| SCHEMBL7023211 | 0.76 | DRD2 (0.42) | ALDH1A1DRD2DRD3DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10565015-B2 | Spiroketal-based C2-symmetric scaffold for asymmetric catalysis | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190084995-A1 | Spiroketal-Based C2-Symmetric Scaffold For Asymmetric Catalysis | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-03-21 | — | — | US | disclosed |
| US-20030113805-A1 | Intrinsically labelled solid support | ZENECA LIMITED, A LONDON CORPORATION | 2003-06-19 | — | — | US | disclosed |
| US-20010007740-A1 | INTRINSICALLY LABELLED SOLID SUPPORT | ZENECA LTD. | 2001-07-12 | — | — | US | disclosed |
| EP-0843656-A1 | INTRINSICALLY LABELLED SOLID SUPPORT | ZENECA LIMITED (GB) | 1998-05-27 | — | — | EP | disclosed |
| WO-1997003931-A1 | INTRINSICALLY LABELLED SOLID SUPPORT | ZENECA LIMITED (GB) | 1997-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10565015-B2 | Spiroketal-based C2-symmetric scaffold for asymmetric catalysis | PKD2, OPA1, PKD1 | ALDH1A1 1985/4885DRD2 2232/4885DRD3 3272/4885 |
| US-20190084995-A1 | Spiroketal-Based C2-Symmetric Scaffold For Asymmetric Catalysis | PKD2, OPA1, PKD1 | ALDH1A1 1985/4885DRD2 2232/4885DRD3 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.